A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome

被引：0
|
作者：
Montesinos, Pau
Al-Ali, Haifa
Alonso-Dominguez, Juan M.
Jentzsch, Madlen
Jongen-Lavrencic, Mojca
Martelli, Maria Paola
Rollig, Christoph
Sica, Simona
Iadevaia, Riham
Yablonski, Kaitlin
Wang, Tianli
Mahmood, Zafar
Koenen, Giedre
Schmidt, Hank
Yang, Jingsong
Yee, Karen
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT124
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A Comparison of Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Treated On versus Off Study
    Percival, Mary-Elizabeth
    Buckley, Sarah
    Othus, Megan
    Halpern, Anna
    Huebner, Emily
    Becker, Pamela
    Shaw, Carole
    Shadman, Mazyar
    Walter, Roland
    Estey, Elihu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S281 - S281
  • [42] Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
    Mollgard, Lars
    Nilsson, Lars
    Kjeldsen, Lars
    Dybedal, Ingunn
    Dufva, Inge Hogh
    Garelius, Hege
    Norgaard, Jan Maxwell
    Linder, Olle
    Ejerblad, Elisabeth
    Astermark, Jan
    Hellstrom-Lindberg, Eva
    BLOOD, 2009, 114 (22) : 52 - 52
  • [43] PHASE 2, OPEN-LABEL STUDY OF E7070, IDARUBICIN AND CYTARABINE IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMA AND HIGH-RISK MYELODYSPLASTIC SYNDROME
    Borthakur, G.
    Cortes, J. E.
    Kadia, T. M.
    Pemmaraju, N.
    Jabbour, E.
    Jain, N.
    Daver, N.
    Kantarjian, H.
    HAEMATOLOGICA, 2014, 99 : 34 - 34
  • [44] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2157 - 2164
  • [45] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    HAEMATOLOGICA, 2024, 109 (07) : 2157 - 2164
  • [46] A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Mattison, Ryan
    Jumonville, Alcee
    Flynn, Patrick James
    Moreno-Aspitia, Alvaro
    Erlichman, Charles
    LaPlant, Betsy
    Juckett, Mark B.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2061 - 2066
  • [47] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
    Halpern, Anna B.
    Buckley, Sarah A.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Perdue, Andrea M.
    Smith, Heather A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Cassone, Stephanie
    Chen, Tara L.
    Stirewalt, Derek L.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [48] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [49] Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
    Cortes, J
    Giles, F
    O'Brien, S
    Thomas, D
    Albitar, M
    Rios, MB
    Talpaz, M
    Garcia-Manero, G
    Faderl, S
    Letvak, L
    Salvado, A
    Kantarjian, H
    CANCER, 2003, 97 (11) : 2760 - 2766
  • [50] Phase I study of Triapine® and cytarabine (ara-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS).
    Yee, KWL
    Cortes, J
    Garcia-Manero, G
    Verstovsek, S
    Ferrajoli, A
    Wierda, WG
    Thomas, D
    Faderl, S
    King, I
    O'Brien, SM
    Sznol, M
    Giles, FJ
    BLOOD, 2005, 106 (11) : 311B - 311B
12345